OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis → A Silent Invasion of America (From The Freeport Society) (Ad) Free IDRSF Stock Alerts $2.36 0.00 (0.00%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$2.36▼$2.3650-Day Range$1.95▼$2.8852-Week Range$1.40▼$8.95VolumeN/AAverage Volume2,919 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Idorsia alerts: Email Address Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Idorsia Stock (OTCMKTS:IDRSF)Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.Read More IDRSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDRSF Stock News HeadlinesJune 13 at 5:00 AM | globenewswire.comIdorsia holds its Annual General Meeting of ShareholdersMay 24, 2024 | finance.yahoo.comIdorsia Ltd (IDRSF)May 23, 2024 | globenewswire.comIdorsia issues invitation to the 2024 Annual General Meeting of ShareholdersMay 21, 2024 | globenewswire.comIdorsia announces changes to Idorsia Executive Committee and Board of DirectorsMay 21, 2024 | globenewswire.comIdorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable valueMay 14, 2024 | globenewswire.comInvitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference callMay 1, 2024 | globenewswire.comIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bondApril 27, 2024 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) Analysts Just Cut Their EPS Forecasts SubstantiallyApril 26, 2024 | finance.yahoo.comJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionApril 23, 2024 | globenewswire.comIdorsia publishes an invitation to a bondholder meetingApril 17, 2024 | finance.yahoo.comIdorsia publishes a Financial Status required for an upcoming bondholder meetingApril 11, 2024 | globenewswire.comIdorsia takes steps to address short-term liquidity needsMarch 22, 2024 | bizjournals.comIdorsia gets FDA approval for high blood pressure drug TryvioMarch 22, 2024 | seekingalpha.comIdorsia: Aprocitentan Approval Is A Vital NewsMarch 22, 2024 | globenewswire.comIdorsia thanks Guy Braunstein for his years of service as he retiresMarch 20, 2024 | msn.comFDA approves Idorsia’s once-daily antihypertensive TryvioMarch 20, 2024 | msn.comIdorsia gets FDA approval for hypertension drug TryvioMarch 20, 2024 | finance.yahoo.comIdorsia Ltd (IDRSF) Stock Historical Prices & Data - Yahoo FinanceMarch 20, 2024 | globenewswire.comUS FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesMarch 8, 2024 | finance.yahoo.comWhat Does The Future Hold For Idorsia Ltd (VTX:IDIA)? These Analysts Have Been Cutting Their EstimatesMarch 7, 2024 | realmoney.thestreet.comKepler Cheuvreux gets more bullish on Idorsia, upgrades sharesFebruary 28, 2024 | markets.businessinsider.comViatris, Idorsia Announce Global Research And Development CollaborationFebruary 6, 2024 | markets.businessinsider.comHere's what to expect from Idorsia's earningsJanuary 10, 2024 | finance.yahoo.comIdorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creationDecember 6, 2023 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insidersSee More Headlines Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IDRSF CUSIPN/A CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Jean-Paul Clozel M.D. (Age 69)CEO & Executive Director Comp: $1.5MMr. André C. Muller (Age 61)Executive VP & CFO Dr. Martine Clozel (Age 69)Executive VP & Chief Scientific Officer Mr. Andrew C. Weiss (Age 56)Senior VP and Head of Investor Relations & Corporate Communications Mr. Julien Gander L.L.M. (Age 45)Senior VP, Group General Counsel & Company Secretary Mr. Alexander Khatuntsev (Age 46)Senior VP & Head of Global Human Resources Dr. Guy Braunstein M.D. (Age 68)Executive VP & Chief Medical Officer Mr. Olivier Lambert (Age 58)Senior VP & Head of Technical Operations Mr. Markus A. Riederer (Age 62)Senior VP & Head of Drug Discovery Biology Mr. Christoph Boss (Age 56)Senior VP & Head of Drug Discovery Chemistry More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IDRSF Stock Analysis - Frequently Asked Questions Should I buy or sell Idorsia stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" IDRSF shares. View IDRSF analyst ratings or view top-rated stocks. How have IDRSF shares performed in 2024? Idorsia's stock was trading at $2.45 at the beginning of 2024. Since then, IDRSF shares have decreased by 3.7% and is now trading at $2.36. View the best growth stocks for 2024 here. Are investors shorting Idorsia? Idorsia saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 7,241,500 shares, a decrease of 5.5% from the May 15th total of 7,663,900 shares. Based on an average daily volume of 3,300 shares, the short-interest ratio is presently 2,194.4 days. View Idorsia's Short Interest. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IDRSF) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Idorsia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.